Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy

J. A. Sprowl, V. Gregorc, C. Lazzari, R. H. Mathijssen, W. J. Loos, A. Sparreboom

Research output: Contribution to journalArticlepeer-review


ABCC2 (MRP2, cMOAT) expression has been implicated in cisplatin resistance in vitro. In mice, cisplatin disposition and toxicity were unaffected by Abcc2 knockout (Abcc2-/-). Moreover, in cancer patients (n = 237), cisplatin pharmacokinetics (P > 0.12) and efficacy (P > 0.41) were not associated with seven of the single-nucleotide polymorphisms (SNPs) in ABCC2. These SNPs were also not correlated with ABCC2 expression in the NCI60 panel (P > 0.26) or with cisplatin-induced cytotoxicity (P = 0.21). These findings highlight the importance of verifying drug-transporter interactions with in vitro tests in humans.

Original languageEnglish
Pages (from-to)1022-1026
Number of pages5
JournalClinical Pharmacology and Therapeutics
Issue number6
Publication statusPublished - Jun 2012

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy'. Together they form a unique fingerprint.

Cite this